Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors

AIM: The BRAF mutation is a rare pathogenetic alternative to KIT/PDGFRA mutation in GIST and causes Imatinib resistance. A recent description of KIT and BRAF mutations co-occurring in an untreated GIST has challenged the concept of their being mutually exclusive and may account for ab initio resista...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossi, Sabrina, Sbaraglia, Marta, Dell'Orto, Marta Campo, Gasparotto, Daniela, Cacciatore, Matilde, Boscato, Elena, Carraro, Valentina, Toffolatti, Luisa, Gallina, Giovanna, Niero, Monia, Pilozzi, Emanuela, Mandolesi, Alessandra, Sessa, Fausto, Sonzogni, Aurelio, Mancini, Cristina, Mazzoleni, Guido, Romeo, Salvatore, Maestro, Roberta, Dei Tos, Angelo P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper: Pathology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058667/
https://www.ncbi.nlm.nih.gov/pubmed/27097112
http://dx.doi.org/10.18632/oncotarget.8768

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058667/
https://www.ncbi.nlm.nih.gov/pubmed/27097112
http://dx.doi.org/10.18632/oncotarget.8768

Ejemplares similares